Search

Your search keyword '"Jarolim, Petr"' showing total 898 results

Search Constraints

Start Over You searched for: Author "Jarolim, Petr" Remove constraint Author: "Jarolim, Petr"
898 results on '"Jarolim, Petr"'

Search Results

201. Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS.

202. Hypertonic Mannitol for the Prevention of Intradialytic Hypotension: A Randomized Controlled Trial

203. The Slavic NBN Founder Mutation: A Role for Reproductive Fitness?

205. Serial Cardiac Troponin Measured Using a High-Sensitivity Assay in Stable Patients With Ischemic Heart Disease

211. Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient Mice

213. Abstract 12644: Growth Differentiation Factor-15 (GDF-15) for Risk Stratification in Patients After an Acute Coronary Syndrome: Insights From the SOLID-TIMI 52 trial

215. The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease

222. Response to Letter Regarding Article, “Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial”

223. Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter

224. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial

228. Prognostic Implications of Low Level Cardiac Troponin Elevation Using High-Sensitivity Cardiac Troponin T

229. GALECTIN-3 FOR HEART FAILURE RISK STRATIFICATION IN PATIENTS AFTER ACUTE CORONARY SYNDROMES (ACS): INSIGHTS FROM THE SOLID-TIMI 52 TRIAL

230. PROGNOSTIC UTILITY OF FIBROBLAST GROWTH FACTOR-23 AFTER AN ACUTE CORONARY SYNDROME

237. The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers.

240. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial

243. Fibroblast Growth Factor-23, Cardiovascular Prognosis, and Benefit of Angiotensin-Converting Enzyme Inhibition in Stable Ischemic Heart Disease

246. PROGNOSTIC IMPLICATIONS OF SIMULTANEOUS BIOMARKER ASSESSMENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: OBSERVATIONS FROM THE SAVOR-TIMI 53 TRIAL

247. RELATIONSHIP BETWEEN DOSE, ANTI-FACTOR XA ACTIVITY, AND OUTCOMES IN PATIENTS RANDOMIZED TO EDOXABAN IN THE ENGAGE AF-TIMI 48 TRIAL

248. CARDIAC TROPONIN I AND B-TYPE NATRIURETIC PEPTIDE PREDICT CLINICAL OUTCOMES IN STABLE RENAL TRANSPLANT RECIPIENTS

Catalog

Books, media, physical & digital resources